Optimising the lymphoma response criteria in the era of targeted therapy.

Optimising the lymphoma response criteria in the era of targeted therapy.

Item
http://www.wikidata.org/entity/Q53220254
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia.Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.XIV. The rationale for combining targeted and biological anti-lymphoma drugs.FDG PET/CT imaging as a biomarker in lymphoma.International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant.The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
P2860

Optimising the lymphoma response criteria in the era of targeted therapy.

Item
http://www.wikidata.org/entity/Q53220254
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Optimising the lymphoma response criteria in the era of targeted therapy.
@en
Optimising the lymphoma response criteria in the era of targeted therapy.
@nl
type
label
Optimising the lymphoma response criteria in the era of targeted therapy.
@en
Optimising the lymphoma response criteria in the era of targeted therapy.
@nl
prefLabel
Optimising the lymphoma response criteria in the era of targeted therapy.
@en
Optimising the lymphoma response criteria in the era of targeted therapy.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Optimising the lymphoma response criteria in the era of targeted therapy.
@en
P2093
P304
P31
P356
10.1016/S1470-2045(11)70132-2
P433
P478
P577
P698